Atossa Therapeutics, Inc. key statistics and ratios
In fiscal 2015, Atossa Therapeutics, Inc. had an operating margin of -725746.2%, debt equal to 0.0% of equity and a current ratio of 1.72. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | LTMSept 2016 |
|---|---|---|---|---|---|---|
| Gross margin | — | 86.4% | 21.7% | 100.0% | — | — |
| Operating margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Net margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Return on equity | — | −150.8% | −136.7% | −145.9% | — | −192.4% |
| Return on assets | −112.1% | −102.6% | −114.5% | −123.3% | −175.0% | −140.7% |
| Asset turnover | 0.00 | 0.10 | 0.07 | 0.00 | 0.00 | 0.00 |
| Current ratio | 1.95 | 1.21 | 4.82 | 4.13 | 1.72 | 5.28 |
| Debt to equity | 64.1% | 0.0% | 0.1% | 0.5% | 0.0% | 0.0% |
| Interest cover (operating income ÷ interest) | n/m | n/m | n/m | n/m | — | — |
| R&D as % of revenue | — | 409.7% | 174.7% | >999% | >999% | >999% |
| Quarter | 2014 Q4Dec 2014 | 2015 Q1Mar 2015 | 2015 Q2Jun 2015 | 2015 Q3Sept 2015 | 2015 Q4Dec 2015 | 2016 Q1Mar 2016 | 2016 Q2Jun 2016 | 2016 Q3Sept 2016 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 100.0% | — | — | — | — | — | — | — |
| Operating margin | <−999% | — | — | — | <−999% | — | — | — |
| Net margin | <−999% | — | — | — | <−999% | — | — | — |
| Current ratio | 4.13 | 3.26 | 4.03 | 2.90 | 1.72 | 2.55 | 1.66 | 5.28 |
| Debt to equity | 0.5% | 0.2% | 0.1% | 0.0% | — | — | — | — |
| R&D as % of revenue | <−999% | — | — | — | >999% | — | — | — |
Moat
Weak moat
How hard Atossa Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Net income has been a median -53.0% of total assets over 10 years.
- Durability 10 / 20
Operating margin has been a median -13706.2%; its worst year was -501813.2%.
- Discipline 0 / 20
The diluted share count rose 6502.0% over five years; stock-based pay has been a median 946.6% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (17 before it).
Compare with peers
More: Biotechnology stocks compared, Health Care sector, rankings of US companies